Drug Therapy for Improving Walking Distance in Intermittent Claudication: A Systematic Review and Meta-analysis of Robust Randomised Controlled Studies

European Journal of Vascular and Endovascular Surgery

Volumn 38, Issue 4, 2009, Pages 463-474

  Momsen, A H ^a   Jensen, M B ^b   Norager, C B ^a   Madsen, M R ^a   Vestersgaard Andersen, T ^c   Lindholt, J S ^c  

^a HERNING HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c VIBORG HOSPITAL   (Denmark)

Author keywords

Drug therapy; Intermittent claudication; Mobility limitation; Randomised controlled trials

Indexed keywords

ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ARGININE; ATORVASTATIN; AVASIMIBE; BUFLOMEDIL; CILOSTAZOL; CLORICROMEN; DEFIBROTIDE; EDETIC ACID; GARLIC EXTRACT; HEPARAN SULFATE; HEPARIN CALCIUM; ILOPROST; INDOBUFEN; INOSITOL NICOTINATE; MESOGLYCAN; NAFTIDROFURYL; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PLACEBO; POLICOSANOL; PROSTACYCLIN; PROSTANOID; SEROTONIN; SIMVASTATIN; SULODEXIDE; TICLOPIDINE; UNINDEXED DRUG; VASODILATOR AGENT;

CHI SQUARE TEST; CLINICAL TRIAL; COCHRANE LIBRARY; DRUG EFFICACY; EMBASE; FOLLOW UP; HUMAN; INTERMITTENT CLAUDICATION; MEDLINE; META ANALYSIS; OUTCOME ASSESSMENT; PEER REVIEW; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREADMILL EXERCISE; WALKING;

CARDIOVASCULAR AGENTS; DOUBLE-BLIND METHOD; EXERCISE TEST; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERMITTENT CLAUDICATION; PERIPHERAL VASCULAR DISEASES; PHOSPHODIESTERASE INHIBITORS; PLATELET AGGREGATION INHIBITORS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING;

EID: 69949098158     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2009.06.002     Document Type: Review

References (43)

1. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., and Fowkes F.G. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg 45 Suppl. S (2007) S5-S67
2. Steg P.G., Bhatt D.L., Wilson P.W., D'Agostino Sr. R., Ohman E.M., Rother J., et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 297 (2007) 1197-1206
3. Regensteiner J.G., Ware Jr. J.E., McCarthy W.J., Zhang P., Forbes W.P., Heckman J., et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 50 (2002) 1939-1946
4. Regensteiner J.G. Current medical therapies for patients with peripheral arterial disease: a critical review. Am J Med 112 (2002) 49-57
5. Hiatt W.R. Medical treatment of the patient with intermittent claudication. J Vasc Technol 18 (1994) 311-315
6. Watson L., Ellis B., and Leng G.C. Exercise for intermittent claudication. Cochrane Database Syst Rev (2008) CD000990
7. Aung P.P., Maxwell H.G., Jepson R.G., Price J.F., and Leng G.C. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev (2007) CD000123
8. Kleijnen J., and Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev (2000) CD000987
9. Sommerfield T., and Hiatt W.R. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev (2004) CD003833
10. Jepson R.G., Kleijnen J., and Leng G.C. Garlic for peripheral arterial occlusive disease. Cochrane Database Syst Rev (2000) CD000095
11. Price J.F., and Leng G.C. Steroid sex hormones for lower limb atherosclerosis. Cochrane Database Syst Rev (2002) CD000188
12. Berglund B., and Eklund B. Reproducibility of treadmill exercise in patients with intermittent claudication. Clin Physiol 1 (1981) 253-256
13. Perakyla T., Tikkanen H., von K.J., and Lepantalo M. Poor reproducibility of exercise test in assessment of claudication. Clin Physiol 18 (1998) 187-193
14. Altstaedt H.O., Berzewski B., Breddin H.K., Brockhaus W., Bruhn H.D., Cachovan M., et al. Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. Prostaglandins Leukot Essent Fatty Acids 49 (1993) 573-578
15. Jadad A.R., Moore R.A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 (1996) 1-12
16. Tonnesen K.H., Albuquerque P., Baitsch G., Gomez A.A., Ibanez F., Kester R.C., et al. Double-blind, controlled, multicenter study of indobufen versus placebo in patients with intermittent claudication. Int Angiol 12 (1993) 371-377
17. Guldager B., Jelnes R., Jorgensen S.J., Nielsen J.S., Klaerke A., Mogensen K., et al. EDTA treatment of intermittent claudication-a double-blind, placebo-controlled study. J Intern Med 231 (1992) 261-267
18. Hiatt W.R., Hirsch A.T., Cooke J.P., Olin J.W., Brater D.C., and Creager M.A. Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. Vasc Med 9 (2004) 18-25
19. Mohler III E.R., Hiatt W.R., and Creager M.A. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 108 (2003) 1481-1486
20. Aronow W.S. Lipid-lowering therapy in high-risk persons. Compr Ther 32 (2006) 68-73
21. Mondillo S., Ballo P., Barbati R., Guerrini F., Ammaturo T., Agricola E., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 114 (2003) 359-364
22. Castano G., Mas F.R., Fernandez L., Gamez R., Illnait J., and Fernandez C. A long-term study of policosanol in the treatment of intermittent claudication. Angiology 52 (2001) 115-125
23. Strandness Jr. D.E., Dalman R.L., Panian S., Rendell M.S., Comp P.C., Zhang P., et al. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. Vasc Endovasc Surg 36 (2002) 83-91
24. Farkouh M.E., and Fuster V. Meta-analysis of small trials: proceed with caution. Nat Clin Pract Nephrol 4 (2008) 115
25. Moher D., Pham B., Ausejo M., Saenz A., Hood S., and Barber G.G. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials. Drugs 59 (2000) 1057-1070
26. Goldsmith D.R., and Wellington K. Naftidrofuryl: a review of its use in the treatment of intermittent claudication. Drugs Aging 22 (2005) 967-977
27. Mohler III E.R., Beebe H.G., Salles-Cuhna S., Zimet R., Zhang P., Heckman J., et al. Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. Vasc Med 6 (2001) 151-156
28. Berthold H.K., Unverdorben S., Degenhardt R., Bulitta M., and Gouni-Berthold I. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled trial. JAMA 295 (2006) 2262-2269
29. Mannava K. Current management of peripheral arterial occlusive disease: A review of pharmacologic agents and other interventions. Am J Cardiovasc Drugs 7 (2007) 59-66
30. Rowlands T.E., and Donnelly R. Medical therapy for intermittent claudication. Eur J Vasc Endovasc Surg 34 (2007) 314-321
31. de Backer T.L., Bogaert M., and Vander S.R. Buflomedil for intermittent claudication. Cochrane Database Syst Rev (2008) CD000988
32. De-Backer T.L., Vander-Stichele R.H., Warie H.H., and Bogaert M.G. Oral vasoactive medication in intermittent claudication: utile or futile?. Eur J Clin Pharmacol 56 (2000) 199-206
33. Leizorovicz A., and Becker F. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study. Circulation 117 (2008) 816-822
34. Creager M.A., Pande R.L., and Hiatt W.R. A randomized trial of iloprost in patients with intermittent claudication. Vasc Med 13 (2008) 5-13
35. Amendt K. PGE1 and other prostaglandins in the treatment of intermittent claudication: a meta-analysis. Angiology 56 (2005) 409-415
36. Robless P., Mikhailidis D.P., and Stansby G.P. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev (2008) CD003748
37. Hiatt W.R., and Krantz M.J. Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Vasc Med 11 (2006) 55-60
38. Labs K.H., Nehler M.R., Roessner M., Jaeger K.A., and Hiatt W.R. Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol. Vasc Med 4 (1999) 239-246
39. Money S.R., Herd J.A., Isaacsohn J.L., Davidson M., Cutler B., Heckman J., et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 27 (1998) 267-274
40. Hood S.C. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. Can Med Assoc J 155 (1996) 1053-1059
41. Duprez D.A. Pharmacological interventions for peripheral artery disease. Expert Opin Pharmacother 8 (2007) 1465-1477
42. Girolami B., Bernardi E., Prins M.H., Ten Cate J.W., Hettiarachchi R., Prandoni P., et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 159 (1999) 337-345
43. de Backer T.L., Vander S.R., Lehert P., and Van B.L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev (2008) CD001368